TNGX ▲ +11.9% - Tango Therapeutics, Inc.
$TNGX - Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
23-OCT-2026 06:30 AM ET
Share this post
More filings for $TNGX
TNGX ▲ +2.0% - Tango Therapeutics, Inc.Nov 9, 2026TNGX ▲ +1.9% - Tango Therapeutics, Inc.Nov 9, 2026TNGX - Tango Therapeutics, Inc. - SEC Filing Update (06-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 6, 2026TNGX ▲ +0.1% - Tango Therapeutics, Inc.Nov 4, 2026TNGX ▲ +0.9% - Tango Therapeutics, Inc.Nov 3, 2026TNGX ▲ +0.6% - Tango Therapeutics, Inc.Oct 16, 2026
View full $TNGX filing history →💬 Comments
Loading comments…
Leave a comment